Aldose reductase inhibition in the treatment of diabetic neuropathy: where are we in 2004?
KH Gabbay - Current diabetes reports, 2004 - Springer
Current diabetes reports, 2004•Springer
Diabetic neuropathy is a major complication of poorly controlled diabetes mellitus. Aldose
reductase, the first enzyme of the polyol pathway, is thought to play a role in initiating the
metabolic damage to peripheral nerves during hyperglycemia. Aldose reductase inhibitors
(ARIs) have been proposed to dampen the flux of glucose through the pathway during
hyperglycemia; however, clinical trials in diabetic patients to demonstrate efficacy in the
prevention or amelioration of diabetic neuropathy have failed thus far. Recent improved …
reductase, the first enzyme of the polyol pathway, is thought to play a role in initiating the
metabolic damage to peripheral nerves during hyperglycemia. Aldose reductase inhibitors
(ARIs) have been proposed to dampen the flux of glucose through the pathway during
hyperglycemia; however, clinical trials in diabetic patients to demonstrate efficacy in the
prevention or amelioration of diabetic neuropathy have failed thus far. Recent improved …
Abstract
Diabetic neuropathy is a major complication of poorly controlled diabetes mellitus. Aldose reductase, the first enzyme of the polyol pathway, is thought to play a role in initiating the metabolic damage to peripheral nerves during hyperglycemia. Aldose reductase inhibitors (ARIs) have been proposed to dampen the flux of glucose through the pathway during hyperglycemia; however, clinical trials in diabetic patients to demonstrate efficacy in the prevention or amelioration of diabetic neuropathy have failed thus far. Recent improved understanding of the pitfalls of past trials and some improved ARIs and clinical evaluation instruments show promise that success in the 20-plus year search for efficacious ARIs may soon be at hand.
Springer